Table 5 Change in diagnosis following MRI.

From: Incremental diagnostic value of 18F-Fluetemetamol PET in differential diagnoses of Alzheimer’s Disease-related neurodegenerative diseases from an unselected memory clinic cohort

Syndromal diagnosis at initial analysis

Change post-MRI in syndromal group, No., %

Comparing to priori threshold (30%), p value

 

(A)

SCD (n = 5)

0

/

 

MCI (n = 41)

18, 44%

p > 0.025

 

Dementia (n = 38)

11, 29%

p > 0.025

 

Total (n = 84)

29, 35%

p > 0.025

 

Etiological diagnosis at initial analysis

Change post-MRI in etiological subgroup, No., %

Comparing to priori threshold (30%), p value

Diagnosis post-MRI of changed subjects

(B)

SCD (n = 5)

0

/

/

AD-related MCI (n = 19)

3, 16%

p > 0.025

2 AD-related Dementia, 1 Non-AD related MCI

Non-AD related MCI (n = 9)

6, 67%

p < 0.025

3 AD-related Dementia, 2 NS MCI, 1 NS Dementia

Non-specific MCI (n = 13)

9, 69%

p < 0.01

2 AD-related MCI, 5 Non-AD MCI, 2 Non-AD related Dementia

AD-related Dementia (n = 24)

4, 17%

p > 0.025

3 NS dementia, 1 Non-AD related Dementia

Non-AD related Dementia (n = 6)

4, 67%

p > 0.025

3 AD-related Dementia, 1 NS Dementia

Non-specific Dementia (n = 8)

3, 38%

p > 0.025

2 AD-related Dementia, 1 Non-AD related Dementia

  1. Significant values are in [bold].
  2. (A) in the syndromal group, (B) in the etiological subgroup.
  3. NS Non-specific.